Skip to main content

Advertisement

SpringerLink
Log in

Overview and Current Advances in Dapsone Hypersensitivity Syndrome

  • Published:
Current Allergy and Asthma Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

As a sulfone antibacterial agent, dapsone has been widely used to treat leprosy. Moreover, dapsone is also used in many immune diseases such as herpetic dermatitis because of its anti-inflammatory and immunomodulatory effects. However, dapsone can cause several adverse effects, the most serious being dapsone hypersensitivity syndrome. Dapsone hypersensitivity syndrome is characterized by a triad of eruptions, fever, and organ involvement, which limits the application of dapsone to some extent.

Recent Findings

In this article, we review current research about the interaction model between HLA-B*13:01, dapsone, and specific TCR in dapsone-induced drug hypersensitivity. In addition to the proposed mechanisms, we also discussed clinical features, treatment progress, prevalence, and prevention of dapsone hypersensitivity syndrome.

Summary

These studies reveal the pathogenesis, clinical features, and prevalence from the perspectives of genetic susceptibility and innate and adaptive immunity in dapsone hypersensitivity syndrome, thereby guiding clinicians on how to diagnose, prevent, and treat dapsone hypersensitivity syndrome.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Data Availability

Not applicable.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Lowe J, Smith M. The chemotherapy of leprosy in Nigeria; with an appendix on glandular fever and exfoliative dermatitis precipitated by sulfones. Int J Lepr. 1949;17:181–95.

    PubMed  CAS  Google Scholar 

  2. Tomecki KJ, Catalano CJ. Dapsone hypersensitivity. The sulfone syndrome revisited Arch Dermatol. 1981;117:38–9. https://doi.org/10.1001/archderm.117.1.38.

    Article  PubMed  CAS  Google Scholar 

  3. Allday EJ, Barnes J. Toxic effects of diaminodiphenylsulphone in treatment of leprosy. Lancet. 1951;2:205–6. https://doi.org/10.1016/s0140-6736(51)91443-2.

    Article  PubMed  CAS  Google Scholar 

  4. Babu T, Panachiyil GM, Ramesh S, Vasudev PH, Ravi MD, Chandrashekhar C. A rare case of dapsone hypersensitivity syndrome and leukemoid reaction with coexisting hepatitis E in a pediatric patient. Hosp Pharm. 2021;56:347–9. https://doi.org/10.1177/0018578720903251.

    Article  PubMed  Google Scholar 

  5. Craig J, MacRae C, Melvin RG, Boggild AK. Case report: a case of type 1 leprosy reaction and dapsone hypersensitivity syndrome complicating the clinical course of multibacillary leprosy. Am J Trop Med Hyg. 2019;100:1145–8. https://doi.org/10.4269/ajtmh.18-0953.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Ordieres Ortega L, Temiño Frade C, Demelo-Rodríguez P. Late onset dapsone hypersensitivity syndrome. Med Clin (Barc). 2019;153:e23–4. https://doi.org/10.1016/j.medcli.2018.11.026.

    Article  PubMed  Google Scholar 

  7. Richardus JH, Smith TC. Increased incidence in leprosy of hypersensitivity reactions to dapsone after introduction of multidrug therapy. Lepr Rev. 1989;60:267–73. https://doi.org/10.5935/0305-7518.19890033.

    Article  PubMed  CAS  Google Scholar 

  8. Chun JS, Yun SJ, Kim SJ, Lee SC, Won YH, Lee JB. Dapsone hypersensitivity syndrome with circulating 190-kDa and 230-kDa autoantibodies. Clin Exp Dermatol. 2009;34:e798-801. https://doi.org/10.1111/j.1365-2230.2009.03527.x.

    Article  PubMed  CAS  Google Scholar 

  9. • You J, Sun L, Zhao Q, et al. Dynamic cytokine profiles combined with enzyme-linked immunospot assay are useful for immunologically confirming the dapsone hypersensitivity syndrome. J Am Acad Dermatol. 2021;84:814–816. https://doi.org/10.1016/j.jaad.2020.06.032. COMMENT: confirmed that the combined detection of IFN-γ, granzyme B, and IL-5 by ELISpot assay showed a good performance in immunologically confirming DHS.

  10. Sun L. Immunologically confirm the dapsone hypersensitivity syndrome by in vivo and in vitro tests. Eur J Immunol. 2019;49:755. https://doi.org/10.1002/eji.201970400.

    Article  Google Scholar 

  11. Wang H, Yan L, Zhang G, et al. Association between HLA-B*1301 and dapsone-induced hypersensitivity reactions among leprosy patients in China. J Invest Dermatol. 2013;133:2642–4. https://doi.org/10.1038/jid.2013.192.

    Article  PubMed  CAS  Google Scholar 

  12. Zhang FR, Liu H, Irwanto A, et al. HLA-B*13:01 and the dapsone hypersensitivity syndrome. N Engl J Med. 2013;369:1620–8. https://doi.org/10.1056/NEJMoa1213096.

    Article  PubMed  CAS  Google Scholar 

  13. Rao PN, Lakshmi TS. Increase in the incidence of dapsone hypersensitivity syndrome–an appraisal. Lepr Rev. 2001;72:57–62. https://doi.org/10.5935/0305-7518.20010009.

    Article  PubMed  CAS  Google Scholar 

  14. Lorenz M, Wozel G, Schmitt J. Hypersensitivity reactions to dapsone: a systematic review. Acta Derm Venereol. 2012;92:194–9. https://doi.org/10.2340/00015555-1268.

    Article  PubMed  Google Scholar 

  15. Wang N, Parimi L, Liu H, Zhang F. A review on dapsone hypersensitivity syndrome among Chinese patients with an emphasis on preventing adverse drug reactions with genetic testing. Am J Trop Med Hyg. 2017;96:1014–8. https://doi.org/10.4269/ajtmh.16-0628.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Zurina Z, Elizawaty O, Thevarajah S, Norlijah O. Dapsone syndrome–first Malaysian paediatric case report. Med J Malaysia. 2012;67:105–7.

    PubMed  CAS  Google Scholar 

  17. Sener O, Doganci L, Safali M, Besirbellioglu B, Bulucu F, Pahsa A. Severe dapsone hypersensitivity syndrome. J Investig Allergol Clin Immunol. 2006;16:268–70.

    PubMed  CAS  Google Scholar 

  18. Sheen YS, Chu CY, Wang SH, Tsai TF. Dapsone hypersensitivity syndrome in non-leprosy patients: a retrospective study of its incidence in a tertiary referral center in Taiwan. J Dermatolog Treat. 2009;20:340–3. https://doi.org/10.3109/09546630802691317.

    Article  PubMed  CAS  Google Scholar 

  19. Kosseifi SG, Guha B, Nassour DN, Chi DS, Krishnaswamy G. The Dapsone hypersensitivity syndrome revisited: a potentially fatal multisystem disorder with prominent hepatopulmonary manifestations. J Occup Med Toxicol. 2006;1:9. https://doi.org/10.1186/1745-6673-1-9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  20. Prussick R, Shear NH. Dapsone hypersensitivity syndrome. J Am Acad Dermatol. 1996;35:346–9. https://doi.org/10.1016/s0190-9622(96)90667-2.

    Article  PubMed  CAS  Google Scholar 

  21. Kumar RH, Kumar MV, Thappa DM. Dapsone syndrome–a five year retrospective analysis. Indian J Lepr. 1998;70:271–6.

    PubMed  CAS  Google Scholar 

  22. Kim GW, Park HJ, Kim HS, et al. Dapsone hypersensitivity syndrome that occurred during treatment of pediatric patient with erythema elevatum diutinum. Ann Dermatol. 2011;23:S290–5. https://doi.org/10.5021/ad.2011.23.S3.S290.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Agrawal S, Agarwalla A. Dapsone hypersensitivity syndrome: a clinico-epidemiological review. J Dermatol. 2005;32:883–9. https://doi.org/10.1111/j.1346-8138.2005.tb00865.x.

    Article  PubMed  Google Scholar 

  24. Garcia A, Yi NJ, Lee KB, et al. Fulminant hepatitis linked to dapsone hypersensitivity syndrome requiring urgent living donor liver transplantation: a case report. Pediatr Transplant. 2014;18:E240–5. https://doi.org/10.1111/petr.12343.

    Article  PubMed  CAS  Google Scholar 

  25. Gavilanes MC, Palacio AL, Chellini PR, Nery JA, Rego JG. Dapsone hypersensitivity syndrome in a lepromatous leprosy patient–a case report. Lepr Rev. 2015;86:186–90.

    Article  PubMed  Google Scholar 

  26. Chogle A, Nagral A, Soni A, Agale S, Jamadar Z. Dapsone hypersensitivity syndrome with coexisting acute hepatitis E. Indian J Gastroenterol. 2000;19:85–6.

    PubMed  CAS  Google Scholar 

  27. Devarbhavi H, Raj S, Joseph TS, Reddy VV, Singh RS. Dapsone-induced liver injury: single centre experience of clinical profile and outcome in 44 cases and review of reported literature. Hepatology. 2016;64:321A.

    Google Scholar 

  28. Kinehara Y, Kijima T, Inoue K, et al. Dapsone hypersensitivity syndrome-related lung injury without eosinophilia in the bronchoalveolar lavage fluid. Intern Med. 2015;54:827–31. https://doi.org/10.2169/internalmedicine.54.3406.

    Article  PubMed  CAS  Google Scholar 

  29. Mannemuddhu SS, Ali R, Kadhem S, Ruchi R. Unusual cause of persistent dyspnea in a patient with nephrotic syndrome: dapsone-induced methemoglobinemia. CEN Case Rep. 2021;10:336–40. https://doi.org/10.1007/s13730-020-00565-8.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Talarico JF, Metro DG. Presentation of dapsone-induced methemoglobinemia in a patient status post small bowel transplant. J Clin Anesth. 2005;17:568–70. https://doi.org/10.1016/j.jclinane.2004.10.011.

    Article  PubMed  Google Scholar 

  31. Grace M. An unusual case of dapsone syndrome. Indian Dermatol Online J. 2011;2:88–90. https://doi.org/10.4103/2229-5178.85999.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Pahadiya HR, Lakhotia M. Dapsone hypersensitivity syndrome with leukemoid reaction and severe thrombocytosis. Cureus. 2021;13: e14026. https://doi.org/10.7759/cureus.14026.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Itha S, Kumar A, Dhingra S, Choudhuri G. Dapsone induced cholangitis as a part of dapsone syndrome: a case report. BMC Gastroenterol. 2003;3:21. https://doi.org/10.1186/1471-230x-3-21.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Alves-Rodrigues EN, Ribeiro LC, Silva MD, Takiuchi A, Fontes CJ. Dapsone syndrome with acute renal failure during leprosy treatment: case report. Braz J Infect Dis. 2005;9:84–6. https://doi.org/10.1590/s1413-86702005000100014.

    Article  PubMed  Google Scholar 

  35. Méry L, Dega H, Prost C. Dubertret L [Dapsone-induced sensory peripheral neuropathy]. Ann Dermatol Venereol. 2003;130:447–9.

    PubMed  Google Scholar 

  36. Fine JD, Katz SI, Donahue MJ, Hendricks AA. Psychiatric reaction to dapsone and sulfapyridine. J Am Acad Dermatol. 1983;9:274–5. https://doi.org/10.1016/s0190-9622(83)80147-9.

    Article  PubMed  CAS  Google Scholar 

  37. Zhu KJ, He FT, Jin N, Lou JX, Cheng H. Complete atrioventricular block associated with dapsone therapy: a rare complication of dapsone-induced hypersensitivity syndrome. J Clin Pharm Ther. 2009;34:489–92. https://doi.org/10.1111/j.1365-2710.2008.00991.x.

    Article  PubMed  CAS  Google Scholar 

  38. Das AK, Jawed Q. Drug-induced acute pancreatitis: a rare manifestation of an incomplete “dapsone syndrome.” Indian J Pharmacol. 2014;46:455–7. https://doi.org/10.4103/0253-7613.135967.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Teo RY, Tay YK, Tan CH, Ng V, Oh DC. Presumed dapsone-induced drug hypersensitivity syndrome causing reversible hypersensitivity myocarditis and thyrotoxicosis. Ann Acad Med Singap. 2006;35:833–6.

    Article  PubMed  Google Scholar 

  40. Pereira CM, Vaz M, Kotha S, Santosh NH. Dapsone hypersensitivity syndrome with myocarditis. J Assoc Physicians India. 2014;62:728–31.

    PubMed  Google Scholar 

  41. Hoogeveen RM, van der Bom T, de Boer HH, et al. A lethal case of the dapsone hypersensitivity syndrome involving the myocardium. Neth J Med. 2016;74:89–92.

    PubMed  CAS  Google Scholar 

  42. Roth M, Gray JT, Peterson PG, Clark PA. Dapsone-induced DRESS after infliximab-induced vasculitis: a case of cerebral infarction in the context of multiple drug reactions. BMJ Case Rep. 2020;13. https://doi.org/10.1136/bcr-2020-237560

  43. Zhu YI, Stiller MJ. Dapsone and sulfones in dermatology: overview and update. J Am Acad Dermatol. 2001;45:420–34. https://doi.org/10.1067/mjd.2001.114733.

    Article  PubMed  CAS  Google Scholar 

  44. Pertel P, Hirschtick R. Adverse reactions to dapsone in persons infected with human immunodeficiency virus. Clin Infect Dis. 1994;18:630–2. https://doi.org/10.1093/clinids/18.4.630.

    Article  PubMed  CAS  Google Scholar 

  45. Marchese M, Leinung M, Shawa H. Drug-induced hypersensitivity reaction: a case of simultaneous thyroiditis and fulminant type 1 diabetes. Avicenna J Med. 2017;7:67–70. https://doi.org/10.4103/ajm.AJM_124_16.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Ceccarelli L, Calisti G, Delle Rose D, et al. Dapsone hypersensitivity syndrome complicated by Scedosporium apiospermum pneumonia in an immunocompetent patient. Infection. 2012;40:459–62. https://doi.org/10.1007/s15010-011-0225-2.

    Article  PubMed  CAS  Google Scholar 

  47. Takahashi H, Tanaka M, Tanikawa A, et al. A case of drug-induced hypersensitivity syndrome showing transient immunosuppression before viral reactivation during treatment for pemphigus foliaceus. Clin Exp Dermatol. 2006;31:33–5. https://doi.org/10.1111/j.1365-2230.2005.01913.x.

    Article  PubMed  CAS  Google Scholar 

  48. Seishima M, Yamanaka S, Fujisawa T, Tohyama M, Hashimoto K. Reactivation of human herpesvirus (HHV) family members other than HHV-6 in drug-induced hypersensitivity syndrome. Br J Dermatol. 2006;155:344–9. https://doi.org/10.1111/j.1365-2133.2006.07332.x.

    Article  PubMed  CAS  Google Scholar 

  49. Zerr DM, Meier AS, Selke SS, et al. A population-based study of primary human herpesvirus 6 infection. N Engl J Med. 2005;352:768–76. https://doi.org/10.1056/NEJMoa042207.

    Article  PubMed  CAS  Google Scholar 

  50. Watanabe H. Recent advances in drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms. J Immunol Res. 2018;2018:5163129. https://doi.org/10.1155/2018/5163129.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  51. Tohyama M, Hashimoto K, Yasukawa M, et al. Association of human herpesvirus 6 reactivation with the flaring and severity of drug-induced hypersensitivity syndrome. Br J Dermatol. 2007;157:934–40. https://doi.org/10.1111/j.1365-2133.2007.08167.x.

    Article  PubMed  CAS  Google Scholar 

  52. Pate DA, Johnson LS, Tarbox MB. Leukocytoclastic vasculitis resolution with topical dapsone. Cutis. 2017;99:426–8.

    PubMed  Google Scholar 

  53. Seneschal J, Guillet S, Ezzedine K, Taïeb A, Milpied B. Alternative procedure to allow continuation of dapsone therapy despite serious adverse reaction in a case of dapsone-sensitive erythema elevatum diutinum. Dermatology. 2012;224:115–9. https://doi.org/10.1159/000337424.

    Article  PubMed  Google Scholar 

  54. Hama N, Abe R, Gibson A, Phillips EJ. Drug-induced hypersensitivity syndrome (DIHS)/drug reaction with eosinophilia and systemic symptoms (DRESS): clinical features and pathogenesis. J Allergy Clin Immunol Pract. 2022;10:1155-1167.e5. https://doi.org/10.1016/j.jaip.2022.02.004.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  55. Husain Z, Reddy BY, Schwartz RA. DRESS syndrome: part II. Management and therapeutics. J Am Acad Dermatol. 2013;68:709.e1–9; quiz 718–20. https://doi.org/10.1016/j.jaad.2013.01.032

  56. Pai S, Munshi R, Nayak C. Fatal dapsone hypersensitivity syndrome with hypothyroidism and steroid-induced diabetes mellitus. Indian J Pharmacol. 2017;49:396–8. https://doi.org/10.4103/ijp.IJP_764_16.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Hashizume H, Ishikawa Y, Ajima S. Is steroid pulse therapy a suitable treatment for drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms? A systematic review of case reports in patients treated with corticosteroids in Japan. J Dermatol. 2022;49:303–7. https://doi.org/10.1111/1346-8138.16230.

    Article  PubMed  CAS  Google Scholar 

  58. Kito Y, Ito T, Tokura Y, Hashizume H. High-dose intravenous immunoglobulin monotherapy for drug-induced hypersensitivity syndrome. Acta Derm Venereol. 2012;92:100–1. https://doi.org/10.2340/00015555-1168.

    Article  PubMed  CAS  Google Scholar 

  59. Sim DW, Yu J, Koh YI. Efficacy of add-on therapy with intravenous immunoglobulin in steroid hyporesponsive DRESS syndrome. Clin Transl Sci. 2022;15:782–8. https://doi.org/10.1111/cts.13201.

    Article  PubMed  CAS  Google Scholar 

  60. Joly P, Janela B, Tetart F, et al. Poor benefit/risk balance of intravenous immunoglobulins in DRESS. Arch Dermatol. 2012;148:543–4. https://doi.org/10.1001/archderm.148.4.dlt120002-c.

    Article  PubMed  CAS  Google Scholar 

  61. Higuchi M, Agatsuma T, Iizima M, et al. A case of drug-induced hypersensitivity syndrome with multiple organ involvement treated with plasma exchange. Ther Apher Dial. 2005;9:412–6. https://doi.org/10.1111/j.1744-9987.2005.00320.x.

    Article  PubMed  Google Scholar 

  62. Nguyen E, Yanes D, Imadojemu S, Kroshinsky D. Evaluation of cyclosporine for the treatment of DRESS syndrome. JAMA Dermatol. 2020;156:704–6. https://doi.org/10.1001/jamadermatol.2020.0048.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Wang CW, Yang LY, Chen CB, et al. Randomized, controlled trial of TNF-α antagonist in CTL-mediated severe cutaneous adverse reactions. J Clin Invest. 2018;128:985–96. https://doi.org/10.1172/jci93349.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Barea-Jiménez N, Calero J, Molina-Negrón D, López Del-Valle LM. Treatment for oral lesions in pediatric patients with Stevens-Johnson’s syndrome: a case report and literature review. Int J Paediatr Dent. 2020;30:489–96. https://doi.org/10.1111/ipd.12615.

    Article  PubMed  Google Scholar 

  65. Sauvetre G, MahÉvas M, Limal N, et al. Cutaneous rash and dapsone-induced hypersensitivity syndrome a common manifestation in adult immune thrombocytopenia. Presentation and outcome in 16 cases. Am J Hematol. 2015;90:E201–2. https://doi.org/10.1002/ajh.24068

  66. Mizukawa Y, Aoyama Y, Takahashi H, Takahashi R, Shiohara T. Risk of progression to autoimmune disease in severe drug eruption: risk factors and the factor-guided stratification. J Invest Dermatol. 2022;142:960-968.e9. https://doi.org/10.1016/j.jid.2021.11.008.

    Article  PubMed  CAS  Google Scholar 

  67. Tangamornsuksan W, Lohitnavy M. Association between HLA-B*1301 and dapsone-induced cutaneous adverse drug reactions: a systematic review and meta-analysis. JAMA Dermatol. 2018;154:441–6. https://doi.org/10.1001/jamadermatol.2017.6484.

    Article  PubMed  PubMed Central  Google Scholar 

  68. Satapornpong P, Pratoomwun J, Rerknimitr P, et al. HLA-B*13:01 Is a predictive marker of dapsone-induced severe cutaneous adverse reactions in Thai patients. Front Immunol. 2021;12: 661135. https://doi.org/10.3389/fimmu.2021.661135.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  69. Tempark T, Satapornpong P, Rerknimitr P, et al. Dapsone-induced severe cutaneous adverse drug reactions are strongly linked with HLA-B*13: 01 allele in the Thai population. Pharmacogenet Genomics. 2017;27:429–37. https://doi.org/10.1097/fpc.0000000000000306.

    Article  PubMed  CAS  Google Scholar 

  70. Cai F, Lucas M, Yun J. Dapsone-induced drug reaction with eosinophilia and systemic symptoms associated with HLA-B*13:01. Intern Med J. 2018;48:363–4. https://doi.org/10.1111/imj.13730.

    Article  PubMed  Google Scholar 

  71. Park HJ, Park JW, Kim SH, et al. The HLA-B*13:01 and the dapsone hypersensitivity syndrome in Korean and Asian populations: genotype- and meta-analyses. Expert Opin Drug Saf. 2020;19:1349–56. https://doi.org/10.1080/14740338.2020.1796965.

    Article  PubMed  CAS  Google Scholar 

  72. Krismawati H, Irwanto A, Pongtiku A, et al. Validation study of HLA-B*13:01 as a biomarker of dapsone hypersensitivity syndrome in leprosy patients in Indonesia. PLoS Negl Trop Dis. 2020;14: e0008746. https://doi.org/10.1371/journal.pntd.0008746.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  73. Bommakanti J, Namoju R, Jabeen T, et al. A case of dapsone hypersensitivity syndrome in an Indian leprosy patient: retrospective screening reveals the genetic connection with HLA-B*13:01. Dermatol Ther. 2020;33: e13825. https://doi.org/10.1111/dth.13825.

    Article  PubMed  Google Scholar 

  74. Chiramel MJ, George R, Daniel D, et al. Case-control study measuring the association between HLA-B*13:01 and dapsone hypersensitivity syndrome in Indian patients. Lepr Rev. 2019;90:371–7.

    Article  Google Scholar 

  75. Chen WT, Wang CW, Lu CW, et al. The function of HLA-B*13:01 involved in the pathomechanism of dapsone-induced severe cutaneous adverse reactions. J Invest Dermatol. 2018;138:1546–54. https://doi.org/10.1016/j.jid.2018.02.004.

    Article  PubMed  CAS  Google Scholar 

  76. Gonzalez-Galarza FF, Christmas S, Middleton D, Jones AR. Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations. Nucleic Acids Res. 2011;39:D913–9. https://doi.org/10.1093/nar/gkq1128.

    Article  PubMed  CAS  Google Scholar 

  77. Liu H, Wang Z, Bao F, et al. Evaluation of prospective HLA-B*13:01 screening to prevent dapsone hypersensitivity syndrome in patients with leprosy. JAMA Dermatol. 2019;155:666–72. https://doi.org/10.1001/jamadermatol.2018.5360.

    Article  PubMed  PubMed Central  Google Scholar 

  78. Nakkam N, Konyoung P, Kanjanawart S, et al. HLA Pharmacogenetic markers of drug hypersensitivity in a Thai population. Front Genet. 2018;9:277. https://doi.org/10.3389/fgene.2018.00277.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  79. Krismawati H, Ferdiana A, Irwanto A, et al. Implementation of genetic screening test to reduce the incidence of dapsone hypersensitivity syndrome among patients with leprosy in Papua, Indonesia: a study protocol. BMJ Open. 2022;12: e057173. https://doi.org/10.1136/bmjopen-2021-057173.

    Article  PubMed  PubMed Central  Google Scholar 

  80. Krismawati H, Maladan Y, Rohman MF. Detection of HLA-B 13:01 gene among Dapsone hypersensitivity patients of leprosy in Papua Ethnics group using sequence based typing and qPCR rapid detection, abstr The 6th International Conference On Biological Science ICBS 2019: “Biodiversity as a cornerstone for embracing future humanity”. 2020.

  81. Palamanda JR, Hickman D, Ward A, Sim E, Romkes-Sparks M, Unadkat JD. Dapsone acetylation by human liver arylamine N-acetyltransferases and interaction with antiopportunistic infection drugs. Drug Metab Dispos. 1995;23:473–7.

    PubMed  CAS  Google Scholar 

  82. Sikka R, Magauran B, Ulrich A, Shannon M. Bench to bedside: pharmacogenomics, adverse drug interactions, and the cytochrome P450 system. Acad Emerg Med. 2005;12:1227–35. https://doi.org/10.1197/j.aem.2005.06.027.

    Article  PubMed  Google Scholar 

  83. Schulkes KJ, Tervaert JW, Rijken F, Haas LE. Dapsone hypersensitivity syndrome not related to G6PD deficiency. BMJ Case Rep. 2015. https://doi.org/10.1136/bcr-2015-212742

  84. Shukkoor AA, Thangavelu S, George NE, Priya S. Dapsone hypersensitivity syndrome (DHS): a detrimental effect of dapsone? A case report Curr Drug Saf. 2019;14:37–9. https://doi.org/10.2174/1574886313666180731123232.

    Article  PubMed  Google Scholar 

  85. Pratoomwun J, Thomson P, Jaruthamsophon K, et al. Characterization of T-cell responses to SMX and SMX-NO in co-trimoxazole hypersensitivity patients expressing HLA-B*13:01. Front Immunol. 2021;12: 658593. https://doi.org/10.3389/fimmu.2021.658593.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  86. Zhao Q, Alhilali K, Alzahrani A, et al. Dapsone- and nitroso dapsone-specific activation of T cells from hypersensitive patients expressing the risk allele HLA-B*13:01. Allergy. 2019;74:1533–48. https://doi.org/10.1111/all.13769.

    Article  PubMed  CAS  Google Scholar 

  87. de Nardo Vanzela T, Bernardes Filho F, Wambier CG, Faria FM, Foss NT, Frade MAC. Th17 response of borderline-lepromatous leprosy inhibits rash manifestation of dapsone hypersensitivity syndrome: case report. Am J Dermatopathol. 2018;40:205–208. https://doi.org/10.1097/dad.0000000000000839.

  88. •• Jiang H, Wang CW, Wang Z, et al. Functional and structural characteristics of HLA-B*13:01-mediated specific T cells reaction in dapsone-induced drug hypersensitivity. J Biomed Sci. 2022;29:58. https://doi.org/10.1186/s12929-022-00845-8. COMMENT: reveal the molecular mechanism in DHS in which dapsone binds directly to both HLA-B*13:01 and the dapsone-specific TCR with specific clonotype.

  89. Alzahrani A, Ogese M, Meng X, et al. Dapsone and nitroso dapsone activation of naı̈ve T-cells from healthy donors. Chem Res Toxicol. 2017;30:2174–86. https://doi.org/10.1021/acs.chemrestox.7b00263.

    Article  PubMed  CAS  Google Scholar 

  90. Xia M, Hu S, Fu Y, et al. CCR10 regulates balanced maintenance and function of resident regulatory and effector T cells to promote immune homeostasis in the skin. J Allergy Clin Immunol. 2014;134:634-644.e10. https://doi.org/10.1016/j.jaci.2014.03.010.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  91. • Zhao Q, Almutairi M, Tailor A, et al. HLA class-II‒restricted CD8(+) T cells contribute to the promiscuous immune response in dapsone-hypersensitive patients. J Invest Dermatol. 2021;141:2412–2425.e2. https://doi.org/10.1016/j.jid.2021.03.014. COMMENT: demonstrate that dapsone interact with the HLA protein to stimulate a cytotoxic T-cell response.

  92. Ng PP, Goh CL. Sparing of tuberculoid leprosy patch in a patient with dapsone hypersensitivity syndrome. J Am Acad Dermatol. 1998;39:646–8. https://doi.org/10.1016/s0190-9622(98)70019-2.

    Article  PubMed  CAS  Google Scholar 

  93. Maddala RR, Ghorpade A, Adulkar S, Polavarapu M. Anatopic response: double sparing phenomenon in a patient with dapsone hypersensitivity syndrome. Indian J Dermatol Venereol Leprol. 2017;83:241–3. https://doi.org/10.4103/0378-6323.193609.

    Article  PubMed  Google Scholar 

  94. Watanabe H, Watanabe Y, Tashiro Y, et al. A docking model of dapsone bound to HLA-B*13:01 explains the risk of dapsone hypersensitivity syndrome. J Dermatol Sci. 2017;88:320–9. https://doi.org/10.1016/j.jdermsci.2017.08.007.

    Article  PubMed  CAS  Google Scholar 

  95. Kommavarapu P, Maruthapillai A, Allada R, Palanisamy K, Chappa P. Simultaneous estimation of degree of crystallinity in combination drug product of abacavir, lamivudine and neverapine using X-ray powder diffraction technique. J Young Pharm. 2013;5:127–32. https://doi.org/10.1016/j.jyp.2013.10.003.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  96. Illing PT, Mifsud NA, Purcell AW. Allotype specific interactions of drugs and HLA molecules in hypersensitivity reactions. Curr Opin Immunol. 2016;42:31–40. https://doi.org/10.1016/j.coi.2016.05.003.

    Article  PubMed  CAS  Google Scholar 

  97. Ozeki T, Mushiroda T, Yowang A, et al. Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum Mol Genet. 2011;20:1034–41. https://doi.org/10.1093/hmg/ddq537.

    Article  PubMed  CAS  Google Scholar 

  98. McCormack M, Alfirevic A, Bourgeois S, et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med. 2011;364:1134–43. https://doi.org/10.1056/NEJMoa1013297.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  99. Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature. 2004;428:486. https://doi.org/10.1038/428486a.

    Article  PubMed  CAS  Google Scholar 

  100. Yue Z, Sun Y, Wang C, et al. Amino acid variants of HLA-DRB1 confer susceptibility to dapsone hypersensitivity syndrome in addition to HLA-B*13:01. J Invest Dermatol. 2018;138:1101–6. https://doi.org/10.1016/j.jid.2017.11.027.

    Article  PubMed  CAS  Google Scholar 

  101. Bishnoi A, Vinay K, Dogra S. HLA screening for dapsone hypersensitivity in India-a long way ahead. JAMA Dermatol. 2019;155:1428–9. https://doi.org/10.1001/jamadermatol.2019.3169.

    Article  PubMed  Google Scholar 

  102. Liu H, Wang Z, Zhang F. HLA screening for dapsone hypersensitivity in India-a long way ahead-in reply. JAMA Dermatol. 2019;155:1429. https://doi.org/10.1001/jamadermatol.2019.2609.

    Article  PubMed  Google Scholar 

  103. Oussalah A, Yip V, Mayorga C, et al. Genetic variants associated with T cell-mediated cutaneous adverse drug reactions: a PRISMA-compliant systematic review-An EAACI position paper. Allergy. 2020;75:1069–98. https://doi.org/10.1111/all.14174.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The authors acknowledge the contributions of all the scientists in this area and we also thank you for the support of the National Natural Science Foundation of China, grant number 82103748, 82173431, and 81972950.

Funding

This work was supported by grants from the grants from the National Key R&D Program of China (2019YFE0113300), National Natural Science Foundation of China (Grant 81972950, 82173431, 82103748), Jiangsu Provincial Medical Key Laboratory, Jiangsu Province Capability Improvement Project through Science, Technology and Education (ZDXYS202204), the Nanjing Incubation Program for National Clinical Research Center (2019060001), and Chinese Academy of Medical Sciences Innovation Fund for Medical Science (2022-I2M-C&T-B-094).

Author information

Author notes

  1. Hai-Qin Jiang and Hong-Sheng Wang contributed equally to this work.

Authors and Affiliations

  1. Hospital of Skin Diseases and Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, St. 12 Jiangwangmiao, Nanjing, Jiangsu, China

    Zhen-Zhen Wang, Rui Zeng, Hai-Qin Jiang & Hong-Sheng Wang

  2. Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China

    Zi-Wei Wu, Chen Wang & Hong-Sheng Wang

Authors
  1. Zhen-Zhen Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rui Zeng
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zi-Wei Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chen Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hai-Qin Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hong-Sheng Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Z.-Z.W. prepared the original draft preparation, Z.-Z.W., R.Z., Z.-W.W. and C.W wrote the main manuscript text, H.-S.W. and H.-Q. J. designed and edited this review. All authors have read and agreed to the published version of the manuscript.

Corresponding authors

Correspondence to Hai-Qin Jiang or Hong-Sheng Wang.

Ethics declarations

Competing interests

The authors declare no competing interests.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Institutional Review Board Statement

Not applicable.

Patents

Not applicable.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, ZZ., Zeng, R., Wu, ZW. et al. Overview and Current Advances in Dapsone Hypersensitivity Syndrome. Curr Allergy Asthma Rep 23, 635–645 (2023). https://doi.org/10.1007/s11882-023-01109-7

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11882-023-01109-7

Keywords

Search

Navigation